Loading
companiesCompany
Profluent
Profluent uses protein language models to design new gene editors (OpenCRISPR-1) and antibodies.
Overview
Profluent, based in Berkeley, uses protein language models to design new gene editors and antibodies. Its OpenCRISPR-1, released in 2024, was the first AI-generated gene editor released openly, and the ProGen family of models underpins its designs. OnCo links it to de novo designed protein binders. Whether AI-designed editors and binders offer advantages in specificity or manufacturability that justify their novelty is the open question for cancer applications. The de novo protein binder page carries the wider field.
Similar pages
- CompanyCradle
Shares De novo designed protein binders, AI-driven drug & target discovery and the tags ai, protein-design.
- CompanyLatent Labs
Shares De novo designed protein binders, AI-driven drug & target discovery and the tags ai, protein-design.
- CompanyIambic Therapeutics
Shares AI-driven drug & target discovery and the tag ai.
- CompanyGenesis Molecular AI (formerly Genesis Therapeutics)
Shares AI-driven drug & target discovery and the tag ai.
- CompanyChai Discovery
Shares the tags ai, protein-design.
- CompanyEvolutionaryScale
Shares the tags ai, protein-design.
- InstitutionInstitute for Protein Design (University of Washington)
Shares the tags ai, protein-design.
- CompanyLila Sciences
Shares AI-driven drug & target discovery and the tag ai.